What happened
ClinicalTrials.gov registry update for Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
SourceClinicalTrials.govclinical updateBiotech
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Clinical/translation signal: Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Factual summary
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
SourceClinicalTrials.govLimitations
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
SourceClinicalTrials.govLinked output
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Studyclinical trialPeople
No reviewed person relationship is attached to this event.
Organizations
Topics
No reviewed topic relationship is attached to this event.
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (NCT05053152)
Timeline
- clinical updateTesting the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study